Disease × agent evidence record

Albiglutide for Type 2 Diabetes: evidence, trials and status

Albiglutide has both completed registered trials and synthesis-level publications linked to Type 2 Diabetes. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit.

8 registered trials 0 recruiting 14 publications Evidence tier A · Strong Score 80.0
Research Tracker › Pairs › Type 2 Diabetes › Albiglutide
Research map, not treatment advice. This page aggregates registry and literature records. It does not evaluate efficacy, dosing or safety for any individual. Discuss any treatment decision with a qualified clinician.

Summary

Albiglutide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. ClinicalTrials.gov lists 8 registered trials linking Albiglutide to Type 2 Diabetes: 8 have completed. The most advanced is Phase 4 (NCT02465515). It plans or enrolled 9463 participants. Registration activity spans 2009 to 2016. The literature layer holds 14 publications for this pair: 5 Cochrane reviews, 3 meta-analyses, 1 systematic review and 5 clinical trial publications. Publication years run from 2020 to 2026. Because at least one synthesis-level source exists (systematic review, meta-analysis or Cochrane review), this pair has been assessed beyond single studies, although the synthesis may concern a different indication.

The RepurpOS disease-intelligence file for Type 2 Diabetes Mellitus ranks 767 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 1.6-1.7% at 7 years on standard care (population-level cohorts UK and US).

Open in Repurposing ExplorerType 2 Diabetes hubType 2 Diabetes biomarkers & interventionsChEMBLOpen Targets

Evidence table

Evidence tierA · Strong
Evidence score80.0 (trials 30.0, literature 30.0, tier 15, approved bonus 5.0)
Registered trials8 total: 0 recruiting, 0 active / not yet recruiting, 8 completed, 0 other
Linked publications14 (5 Cochrane reviews, 5 clinical trial publications, 3 meta-analyses, 1 systematic review)
Agent typeBiologic
Development stage (any indication)Approved
Mechanism / classNot recorded
Data sourcesOpen Targets, ChEMBL
How the evidence score is calculated
  • Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
  • Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
  • The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
  • Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
  • The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.

Registered clinical trials

NCT IDTitleStatusPhaseEnrolment
NCT02496221A Study Evaluating the Effect of Albiglutide on Gallbladder Emptying in Healthy Subjects
2015
completedPhase 420
NCT02465515Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
2015
completedPhase 49,463
NCT00838903Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes
2009
completedPhase 31,049
NCT00839527A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes
2009
completedPhase 3685
NCT01357889Pharmacokinetics/Pharmacodynamics of Albiglutide
2011
completedPhase 2283
NCT01475734Albiglutide Glucose Clamp Study in Subjects With Type 2 Diabetes
2011
completedPhase 244
NCT01406262Albiglutide Thorough ECG Study in Healthy Volunteers
2011
completedPhase 194
NCT02846233Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?
2016
completedNot applicable22

Search ClinicalTrials.gov for newer studies

Published literature

Run the live PubMed search

Mechanism and notes

No mechanism of action is recorded for this pair in the source databases.

OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Frequently asked questions

Is Albiglutide approved for Type 2 Diabetes?

Albiglutide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Type 2 Diabetes would be drug repurposing rather than first-in-human development. This does not mean it is approved for Type 2 Diabetes. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.

Is Albiglutide in clinical trials for Type 2 Diabetes?

ClinicalTrials.gov lists 8 registered trials linking Albiglutide to Type 2 Diabetes: 8 have completed. The most advanced is Phase 4 (NCT02465515). It plans or enrolled 9463 participants. Registration activity spans 2009 to 2016.

What does the evidence show for Albiglutide in Type 2 Diabetes?

Albiglutide has both completed registered trials and synthesis-level publications linked to Type 2 Diabetes. That is the strongest profile in this database, but the summaries here do not extract effect sizes, so read the linked reviews for direction and magnitude of benefit. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.

Cite this page

Open Source Medicine Foundation. Albiglutide for Type 2 Diabetes: evidence, trials and status. OSMF Research Tracker. Updated 2026-07-05. https://research.opensourcemed.info/pairs/type-2-diabetes/albiglutide.html

Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.

Get OSMF research updates on Substack

This is a research map, not treatment advice. Evidence tiers and scores summarise what has been studied, not whether a treatment works or is safe for you.